Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 1 7Phase 3 6Phase 1/2 5Phase NA 2Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 2

Interventions

Endoscopic Mucosal Resection 3lutetium Lu 177 dotatate 2Lutetium-177 2Liquid Biopsy 2Data Collection 2pentetreotide 1fluorodopa F 18 1copper dotatate CU-64 1Yttrium-90 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Standard of Care 1Specimen Handling 1Single Photon Emission Computed Tomography Computed Tomography 1Serum Albumin 1Robotic Surgical Procedures 1Resveratrol 1Respiratory Therapy 1Referral and Consultation 1Radiofrequency Ablation 1Quality of Life 1Poly(ADP-ribose) Polymerase Inhibitors 1Palliative Care 1Octreotide 1Nutrition Assessment 1Needles 1Magnetic Resonance Spectroscopy 1Laparoscopy 1Drug Therapy 1Diet Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × lutetium Lu 177 dotatate × NET × Clear all
NCT02743741 2025-12-03

Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

University Health Network, Toronto

Phase NA Active not recruiting
195 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05513469 2023-04-07

Radio-Marker

Erasmus Medical Center

Phase NA Unknown
20 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡